青光眼候选miRNA生物标志物的鉴定
PURPOSE: Glaucoma, a leading cause of blindness worldwide, often remains undetected until irreversible vision loss has occurred. Treatments focus on lowering intraocular pressure (IOP), the only modifiable and readily measurable risk factor.…
要点
- 血浆miRNA水平与房水miRNA水平相关,血浆可作为易获取的生物标志物来源。
- miR-637、miR-1306-5p和miR-3159联合诊断青光眼的AUC为0.91±0.008。
核心结论
- 特定miRNA可作为青光眼的潜在生物标志物,并有助于理解青光眼的分子过程。
研究设计与样本
- 研究纳入两个种族队列中接受择期手术的青光眼或剥脱综合征患者(n=33)与对照者(n=31),采集血浆和房水。
- 使用定制miRNA阵列检测372种miRNA,并用Ingenuity Pathway Analysis(IPA)和DIANA生物信息学工具进行靶点预测和通路分析。
主要发现
- 血浆miRNA水平与房水miRNA水平相关。
- miR-637、miR-1306-5p和miR-3159联合区分青光眼患者与对照的AUC=0.91±0.008,敏感性85.0%,特异性87.5%。
关键数值与推荐
- 差异表达阈值:循环miRNA在患者中较对照至少高1.5倍。
- miR-4667-5p的P=4.1×10-5,miR-99b-3p的P=4.8×10-5,miR-637的P=5.1×10-5。
- miR-637、miR-1306-5p和miR-3159联合诊断的AUC=0.91±0.008,敏感性85.0%,特异性87.5%。
临床怎么用
- 血浆miRNA检测有潜力作为青光眼或剥脱综合征的微创辅助生物标志物。
- miR-637、miR-1306-5p和miR-3159组合可作为候选诊断面板进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glaucoma, a leading cause of blindness worldwide, often remains undetected until irreversible vision loss has occurred. Treatments focus on lowering intraocular pressure (IOP), the only modifiable and readily measurable risk factor. However, IOP can vary and does not always predict disease progression. MicroRNAs (miRNAs) are promising biomarkers. They are abundant and stable in biological fluids, including plasma and aqueous humor (AqH). We aimed to identify differentially expressed miRNAs in AqH and plasma from glaucoma, exfoliation syndrome (XFS), and control subjects. METHODS: Plasma and AqH from two ethnic cohorts were harvested from glaucoma or XFS (often associated with glaucoma, n = 33) and control (n = 31) patients undergoing elective surgery. A custom miRNA array measured 372 miRNAs. Molecular target prediction and pathway analysis were performed with Ingenuity Pathway Analysis (IPA) and DIANA bioinformatical tools. RESULTS: Levels of miRNAs in plasma, a readily accessible biomarker source, correlated with miRNA levels in AqH. Twenty circulating miRNAs were at least 1.5-fold higher in glaucoma or XFS patients than in controls across two ethnic cohorts: miR-4667-5p (P = 4.1 × 10-5), miR-99b-3p (P = 4.8 × 10-5), miR-637 (P = 5.1 × 10-5), miR-4490 (P = 5.7 × 10-5), miR-1253 (P = 6.0 × 10-5), miR-3190-3p (P = 3.1 × 10-4), miR-3173-3p (P = 0.001), miR-608 (P = 0.001), miR-4725-3p (P = 0.002), miR-4448 (P = 0.002), and miR-323b-5p (P = 0.002), miR-4538 (P = 0.003), miR-3913-3p (P = 0.003), miR-3159 (P = 0.003), miR-4663 (P = 0.003), miR-4767 (P = 0.003), miR-4724-5p (P = 0.003), miR-1306-5p (P = 0.003), miR-181b-3p (P = 0.004), and miR-433-3p (P = 0.004). miR-637, miR-1306-5p, and miR-3159, in combination, allowed discrimination between glaucoma patients and control subjects (AUC = 0.91 ± 0.008, sensitivity 85.0%, specificity 87.5%). CONCLUSIONS: These results identify specific miRNAs as potential biomarkers and provide insight into the molecular processes underlying glaucoma.
引用
- Hindle AG, Thoonen R, Jasien JV, et al. Identification of Candidate miRNA Biomarkers for Glaucoma. Invest Ophthalmol Vis Sci. 2019. PMID: 30629727. doi:10.1167/iovs.18-24878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。